PJI is a devastating complication of joint arthroplasty, with an average 1-year incidence of 0.25--1.0% for primary THR and 0.4--2% for primary TKR ([@CIT0118], [@CIT0016], [@CIT0079], [@CIT0103]). The incidence rate of infection in revision surgery is even higher, with an estimated rate of 3.2--5.6% for both hips and knees ([@CIT0106]). Moreover, infection accounts for up to 12% of the indications for revision hip arthroplasty, and 22% for revision knee arthoplasty, as recorded in the National Joint Registry ([@CIT0001]). The overall infection burden is projected to rise by 4% between 2005 and 2030 for both primary and revision hip and knee arthroplasties ([@CIT0087], [@CIT0017]).

The formation of biofilms is intrinsic to the pathogenesis of PJI, and in this review we consider the impact of biofilms in PJI, explore the diagnostic challenges of biofilm-related prosthetic joint infections (BRPJIs), and evaluate the various measures that are aimed at their eradication.

The significance of biofilms in arthroplasty {#ss1}
============================================

Over 65% of all human infections are estimated to be biofilm-related ([@CIT0102], [@CIT0160]). In addition, over 12 million people in the USA are reported to be affected by biofilm-related infections (BRIs) every year, with an estimated annual economic burden of \$6 billion ([@CIT0113], [@CIT0162]). Of these, BRI in orthopedic practice is one of the most significant, due to bone and joint sequelae. The surfaces of commonly used orthopedic components such as titanium (and its alloys), stainless steel, cobalt-chromium, various polymeric biomaterials (e.g. ceramics, hydroxyapatite, and polyethylene), and polymethylmethacrylate (PMMA) cement are all susceptible to colonization by biofilm-forming bacteria ([@CIT0060], [@CIT0059], [@CIT0131]).

The biofilm life cycle {#ss2}
======================

A biofilm can be described as a structured aggregation of microbial cells of one or several species, encased in a self-produced matrix and adherent to a biotic or an abiotic surface ([@CIT0031], [@CIT0130], [@CIT0112]). The biofilm matrix is composed of exopolysaccharides (also called extrapolymeric substances), proteins, teichoic acids, lipids, and extracellular DNA ([@CIT0013]). The reason why antibiotics have poor activity against biofilms is not entirely understood. It is thought that the existence of slow or non-growing cells within the biofilm, the presence of bacterial subpopulations with different phenotypic levels of resistance within biofilms, overexpression of genes, and stress responses to hostile environmental conditions all contribute to the resistance of biofilms ([@CIT0029], [@CIT0093], [@CIT0099]). Although, biofilms are often described as being attached to surfaces, they can also form at interfaces of spatially distinct microenvironments or as aggregated masses of free-floating cells, which can exhibit features similar to those of a typical surface-associated biofilm ([@CIT0027], [@CIT0064]).

The development of a biofilm on an orthopedic implant can be described as a 4-stage process: (1) cell adhesion, (2) cell aggregation, (3) biofilm maturation, and (4) cellular detachment.

*Stage 1: Cell adhesion:* This process starts within the first few seconds and extends to approximately 2 h of exposure ([@CIT0112]). It is mediated by factors such as the implant surface charge, hydrophobicity, topography, and exposure time ([@CIT0131]). During arthroplasty, host proteins such as fibrinogen, fibronectin, and vitronectin are absorbed onto the surfaces of orthopedic implants shortly after insertion, resulting in the formation of a conditioning film ([@CIT0157], [@CIT0131]). This state of the biomaterial surface enhances bacterial colonization through interactions between bacterial proteins and host proteins ([@CIT0067], [@CIT0091]).

*Stage 2: Cellular aggregation:* At this stage, there is a multilayer cellular proliferation, as well as cell-to-cell adhesion, culminating in the formation of microcolonies of one or several species. These organized structures are then surrounded by a self-produced extracellular polysaccharide matrix (slime) with a resultant enclosed volume of high microbial density ([@CIT0069]). Thus, a biofilm is progressively established on the colonized surface. This process is mediated both by microbial surface components recognising adhesive matrix molecules (MSCRAMMs) and the polysaccharide intercellular adhesin (PIA) ([@CIT0117], [@CIT0066], [@CIT0097], [@CIT0133], [@CIT0134], [@CIT0137]). For biofilm- forming staphylococci which do not produce PIA, cell-to-cell adhesion is mediated by biofilm-adhesive proteins such as the accumulation-associated protein (Aap), extracelluar matrix protein (Emp), protein A, and *Staphylococcus aureus* surface protein G (SasG) ([@CIT0071], [@CIT0132], [@CIT0026], [@CIT0104], [@CIT0024], [@CIT0053]). At this stage, the biofilm is still relatively unstable and susceptible to eradication.

*Stage 3: Biofilm maturation:* To achieve maturation, physiological changes such as regulation of pili, flagellae, and exopolysaccharides occur within the biofilm ([@CIT0028], [@CIT0090]). This stage is mainly regulated by the accessory gene regulator (Agr) quorum-sensing system ([@CIT0152], [@CIT0153], [@CIT0155], [@CIT0121]). When mature, the biofilms assume sessile forms, which are more resistant to eradication ([@CIT0069]).

*Stage 4: Cellular detachment:*On maturation, large biofilms may release planktonic (free-floating) forms from their surfaces, which then disperse to cause further local invasion or seeding of distant sites, thus initiating an entirely new cycle. Proteases and the Agr system regulate this phase.

Classification of PJIs {#ss3}
======================

A number of classifications are offered in the literature, one of the most popular being by Trampuz and Zimmerli ([@CIT0168], [@CIT0144]). These authors classified PJIs---according to the onset of symptoms after implantation---into: (1) early infection (\< 3 months postoperatively), typically caused by highly virulent microorganisms such as *Staphylococcus aureus* or Gram-negative bacilli (such as *E. coli*); (2) delayed infection (3--24 months postoperatively), typically caused by less virulent bacteria such as coagulase-negative staphylococci or *Priopionibacterium acnes*; and (3) late infection ( \> 24 months), typically caused by virulent bacteria such as *Staphylococcus aureus*, streptococci, and Gram-negative bacilli.

Both early and delayed infections usually occur as a result of perioperative contamination and are considered to be the most common cause of biomaterial-related infections ([@CIT0005], [@CIT0055], [@CIT0094]). These infections are generally associated with both local and systemic symptoms, and in addition induce inflammatory responses that are accompanied by raised laboratory inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white cell count levels. Blood cultures and tissue cultures can also be used to detect infection during the early stages.

Late infections generally occur after a relatively asymptomatic postoperative period and are usually consequent to hematogenous seeding---most commonly from skin and soft tissue infections ([@CIT0006], [@CIT0098]). Seeding may also occur from urinary, respiratory, or gastrointestinal tract infections.

Definition and diagnosis of PJI {#ss4}
===============================

There is as yet no universally accepted definition of PJI, but 2 large international infection workgroups---the international consensus group on periprosthetic joint infection ([@CIT0025], [@CIT0116]) and the Infectious Diseases Society of America ([@CIT0114])---recently published consensus documents aimed at standardizing the definition of PJI, which readers may consult.

Based on an extensive review of the literature published between 1966 and 2011, a randomized clinical trial from a single-center, non-randomized retrospective case series, and case reports, the Infectious Diseases Society of America (IDSA) recommended that from the history and physical examination, PJI should be suspected in patients with any of the following: (1) a sinus tract or persistent wound drainage over a joint, (2) acute onset of a painful prosthesis, or (3) a chronically painful prosthesis at any time postoperatively, particularly in the absence of a pain-free period in the first few years after implantation or if there is a history of wound-healing problems or superficial wound infection ([@CIT0114]).

Identification of biofilm-related PJI can be more challenging, as these infections can develop over a period of a few months to years, exist innocuously, and give few clinical signs ([@CIT0084]). Conventional antimicrobial therapy is able to resolve systemic symptoms from pathogens in their planktonic form while the sessile forms remain unaffected ([@CIT0110], [@CIT0064], [@CIT0120]). Failure of conventional culture methods to isolate a causative pathogen in these cases can often result in a diagnostic conclusion of "aseptic failure", even in the presence of compelling clinical signs ([@CIT0012], [@CIT0030]). In an attempt to address this dilemma, Hall-Stoodley et al. ([@CIT0064]) recently described a number of indicators of a possible BRI. These are not intended for use as diagnostic criteria (and thus are not accompanied by a scoring system) but are meant for use as an adjunct for diagnosis. They include: (1) history of persistent or recurrent joint infection, (2) infection localized to a particular implant site (evidenced by features such as swelling, pain, redness, warmth, tenderness, and functional limitation), (3) recalcitrance of infection despite adequate use of appropriate antibiotic therapy (based on antibiotic sensitivity testing for cultured pathogens), (4) ineffective treatment as evidenced by the persistent presence of cell clusters (identified microscopically), together with host inflammatory cells at the same site of infection, (5) culture-negative results despite a high degree of clinical suspicion of infection, and (6) direct visualization, by microscopy, of cellular aggregation of matrix-encased bacteria, associated with a surface.

Analytical challenges of biofilm-related PJI {#ss5}
============================================

Conventional culture was originally developed by Robert Koch more than 150 years ago and it is still the approved method for detecting and identifying bacteria in medical microbiology ([@CIT0013], [@CIT0042]). The sensitivity rate of culture can be as low as 19% ([@CIT0108], [@CIT0063], [@CIT0147], [@CIT0123]) due to the inability to detect bacteria growing in biofilms. To improve detection of infection, other investigative methods are being explored---2 examples of which are molecular techniques and ultrasound.

Molecular methods {#ss6}
=================

Polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) are 2 popular types of molecular methods that are capable of identifying pathogens up to 80--100% of the time in cases of chronic/persistent infection ([@CIT0125], [@CIT0063], [@CIT0140], [@CIT0046], [@CIT0124]). By combining 16S rRNA gene PCR analysis with direct confocal microscopic examination (CLSM) of effusions from the affected ear, Hall-Stoodley et al. were able to diagnose a biofilm-based infection in an otherwise culture-negative otitis media ([@CIT0063]).

The high cost, heavy reliance on expertise, susceptibility to sample contamination, and the lack primers relevant to diagnosis of PJI currently limit the routine use of molecular techniques in medical microbiology. At present, they are probably best reserved for culture-negative cases (van [@CIT0150], [@CIT0092], [@CIT0167]).

Ultrasound {#ss7}
==========

This is a cheaper and more readily available tool, which has been shown to improve infection detection rates ([@CIT0147], [@CIT0086], [@CIT0105], [@CIT0136]). Upon application of ultrasound to liquid medium containing explanted orthopedic prostheses, ultrasonic waves are propagated through the liquid, which creates millions of microscopic air bubbles (a process called cavitation). These bubbles then implode, generating energy high enough to disrupt adherent biofilms and to release the bacteria within them into the liquid ([@CIT0145]). These disaggregated bacterial cells can then be cultured. [@CIT0147] prospectively compared cultures of samples obtained by sonication of explanted hip and knee prostheses from 331 patients (252 with aseptic failure and 79 with PJI) with conventional culture of periprosthetic tissue. The sensitivities of periprosthetic tissue cultures and sonicated fluid cultures regarding infection were 61% and 79%, respectively. Sonication is being increasingly used in many orthopedic centers, with reported benefits ([@CIT0148], [@CIT0045], [@CIT0070], [@CIT0047], [@CIT0075], [@CIT0076]). Combination of sonication with PCR further enhances the sensitivity to infection ([@CIT0003], [@CIT0046], [@CIT0056], [@CIT0014]).

Although routine sonication of explanted prostheses may not be necessary, it can be helpful for selection of antimicrobial agents by improving bacterial detection, especially in cases where preoperative joint aspiration has given culture-negative results. For diagnosis, low-intensity ultrasound (US) should be used, as high-intensity US can result in bacterial death.

US of high intensity has been shown to be useful for the eradication of biofilms. [@CIT0044] compared bacteria survival on bone cement implanted into New Zealand rabbits, in the presence or absence of ultrasound. They found that in combination with gentamicin, pulsed US applied continuously for up to 72 h at a frequency of 28.48 Hz and a maximum intensity of 0.5 W/cm^2^ resulted in a 58--69% reduction in viable *E. coli* biofilm on bone cement compared to the negative controls.

Previously, [@CIT0022] had performed an in vivo experiment similar to that of Ensing et al., in which they also investigated the effect of ultrasound and antibiotics, but in their study they used vancomycin rather than gentamicin. They infected rabbits with biofilm-producing *Staphylococcus epidermidis* and, like Ensing et al., applied ultrasound. Statistically significant reductions in viable bacteria were seen with the combination of US and vancomycin after 48h, however, at times shorter than this, there were no significant reductions in viable bacteria counts.

The mechanism by which the combination of US and antibiotic exerts its effect is not clearly understood, but it is postulated that ultrasound probably induces an increase in cement porosity, thereby enhancing elution of the antibiotic. Furthermore, high-intensity US possibly also has a disruptive effect on the bacterial cell wall itself, leading to cell death.

There does not appear to be a clear consensus in the literature regarding the ideal frequency and intensity to use for either diagnostic or therapeutic purposes in PJI management. Despite the fact that pulsed US appears to be safe for use in treating experimentally induced infections in rabbits, the same cannot be said for spontaneous infections in humans---if US is to be used at infection sites with implants in situ.

Advanced imaging of biofilms {#ss8}
============================

Confocal laser scanning microscopy (CLSM) and scanning electron microscopy (SEM) are advanced imaging techniques that can be used to visualize biofilms.

CLSM allows non-destructive examination of the layers of a biofilm at different depths, and in addition generates high-resolution three-dimensional (3-D) images ([@CIT0089], [@CIT0078], [@CIT0126]). Using CLSM, [@CIT0139] were able to demonstrate viable bacteria in biofilm in joint fluid, wound tissue, and bone cement retrieved from an infected total elbow arthroplasty, which had consistently yielded negative cultures for over 5 years.

SEM does not generate 3-D images but provides more easily discernable images depicting the co-aggregation of microbial cells of a biofilm. The [Figure](#F1){ref-type="fig"} is an SEM image of a *Staphylococcus epidermidis*biofilm on bone cement. Unfortunately, SEM images often do not reveal the ECM structure of the biofilm, as the preparation process often results in the loss or distortion of the ECM ([@CIT0048], [@CIT0080], [@CIT0156]).

![Scanning electron micrograph of biofilms on PMMA cement.](ORT-86-147-g001){#F1}

Management of PJI {#ss9}
=================

Antibiotics {#ss10}
-----------

Rifampicin has been commended in the literature for its efficiency in treating PJIs, especially those associated with biofilms. Rifampicin, daptomycin, ciprofloxacin, vancomycin, and amikacin have all been reported to penetrate biofilms ([@CIT0040], [@CIT0033], [@CIT0166], [@CIT0138], [@CIT0135]). It is, however, unclear from these studies whether the antimicrobials had any detrimental effects on the bacteria in the biofilms.

[@CIT0129] compared the activities of daptomycin, linezolid, and tigecycline with those of vancomycin, minocycline, and rifampin against catheter-related methicillin-resistant *Staphylococcus aureus* (MRSA) embedded in biofilm using an in vitro silicon disk biofilm colonization model. They were able to demonstrate that daptomycin, minocycline, and tigecycline were significantly more effective than vancomycin or linezolid in inhibiting MRSA bacteria embedded in biofilm. In addition, they found rifampicin to be the most effective in reducing the bacterial load of MRSA biofilms; however, this effect was short-lived due to the rapid emergence of resistance within a few days of using rifampicin as a sole agent. Rifampicin was then used in combination with other antibiotics, and this was found to expedite the elimination of MRSA colonization in biofilm. [@CIT0077] compared the activity of daptomycin (alone and with rifampicin) with the activities of vancomcyin, linezolid, and levofloxacin against MRSA strain ATCC 43300 in a guinea pig foreign-body infection model. They found that daptomycin at a high once-daily dose (corresponding to the 6 mg/kg safe dose in humans), in combination with rifampicin, showed the highest activity against planktonic and biofilm MRSA. This combination was found to achieve a cure rate higher than that achieved with vancomycin plus rifampicin, and also to prevent the emergence of rifampicin resistance. Moreover, the vancomycin-rifampicin combination did not prevent the emergence of rifampicin resistance. In the same study, the combination of levofloxacin with rifamipcin was also found to be efficacious against planktonic and adherent MRSA with cure rates similar to that of rifampicin in combination with daptomycin ([@CIT0146]). Rifampicin should ideally be used in combination with other antibiotics to avoid rapid emergence of resistance, which tends to occur when rifampicin is used as monotherapy.

The literature strongly suggests that eradication of biofilms, as well as adequate protection against infections, is better achieved by using combinations of antibiotics rather than single therapy ([@CIT0149], [@CIT0039], [@CIT0068], [@CIT0115]). Moreover, combining 2 or more antibiotics can minimize the emergence of resistance, provide synergy, broaden the antimicrobial spectrum, and prolong drug elution ([@CIT0109], [@CIT0062], [@CIT0163]). The [Table](#T1){ref-type="table"} provides details of some putative biofilm-active antibiotics.

###### 

Putative biofilm-active antibiotics

  -------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotic                                               Class                                                   MOA                                                                                                                                                                 Spectrum of activity                                                                                                            Important side effects [**^b^**](#T1-F2){ref-type="fn"}
  Rifampicin [**^a^**](#T1-F1){ref-type="fn"}t~1/2~: 4 h   Rifamycin                                               BactericidalInhibition of bacterial RNA synthesis                                                                                                                   Gram-positive and -negative bacteria                                                                                            Nausea, gastrointestinal disturbances, hepatotoxicity, thrombocytopenia, rash, red discoloration of urine, flu-like symptoms
  Daptomycint~1/2~: 9 h                                    Lipopetide                                              BactericidalInsertion of hydrophobic tail into cell membrane, resulting in membrane depolarization and cell death                                                   Gram-positive bacteria including MRSA, VRSA, VRE, and PRSP. Log- and stationary-phase of bacteria                               Nausea, vomiting, diarrhea, hypertension and hypotension, myopathy, neuropathy, urethritis, anemia, hypokalemia, arthralgia
  Linezolidt~1/2~: 6 h                                     Oxazolidinones                                          BacteriostaticBinds to the bacterial 23S ribosomal RNA of the 50S subunit, thus preventing the formation of a functional 70S complex. Production by MSSA and MRSA   Gram-positive bacteria including MRSA, MSSA, CoNS, and enterococci including VRE.Good tissue distribution and bioavailability   Nausea, vomiting, diarrhea, thrombocytopenia, myelosuppression, reversible optic neuritis, irreversible peripheral neuropathy, serotonin syndrome
  Tigecyclinet~1/2~: 42 h                                  Glycylcylines (synthetic derivative of tetracyclines)   BacteriostaticBinds 30S bacterial ribosomal subunit and prevents binding of tRNA to the mRNA ribosome complex                                                       Active against Gram-positive bacteria (including VRE and MRSA), Gram-negative bacilli, and anaerobes                            Nausea, vomiting, diarrhea, sore mouth and throat, dysphagia, vitamin B complex deficiency, dental abnormalities, hepatotoxicity
  Minocyclinet~1/2~: 15 h                                  Tetracyclines                                           Same as tigecycline                                                                                                                                                 Similar to tigecycline and also active against *Neisseria meningitidis*                                                         Similar to tigecycline and in addition, vestibular disturbances with dizziness, tinnitus, and impaired balance---especially in women
  Vancomycint~1/2~: 8 h                                    Glycopeptides                                           BactericidalInhibits bacterial cell wall formationInterferes with peptidoglycan synthesis                                                                           Gram-positive bacteria. MRSA                                                                                                    Tinnitus, deafness (reversible on cessation of drug), nephrotoxicity, maculopapular rash (with rapid i.v. infusion)
  -------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------

Should ideally be used as combination therapy to avoid rapid emergence of resistance.

MOA: mechanism of action; MRSA: methicillin-resistent Staphylococcus aureus; MSSA: methicillin-sensitive Staphylococcus aureus;

VRE: vancomycin-resistent enterococcus; PRSP: penicillin-resistant Streptococcus pneumoniae; CoNS: coagulase-negative staphylococci; t~1/2~: serum half-life of drug.

These side effects are generally attributed to systemic administration.

The ideal course of treatment of PJI using systemically administered antibiotics is still under debate. [@CIT0143] suggested a total period of between 3 and 6 months, with intravenous administration being continued for 2--6 weeks prior to a switch to oral alternatives.

Since its conceptualization by Buchholz and Engelbrecht in 1970 ([@CIT0019], [@CIT0020]), the use of antibiotic-loaded acrylic cement (ALAC) for the management of PJI has been common practice among many orthopedic surgeons. Furthermore, ALAC is an independent factor proven to reduce the incidence of PJI ([@CIT0032], [@CIT0074], [@CIT0111]). Unfortunately, only about 10% of the antibiotic incorporated is ever released from the cement ([@CIT0158]). Moreover, the potential of ALAC to induce antibiotic resistance due to late release of antibiotic at sub-inhibitory concentrations, is of significant concern, although the use of combination antimicrobial therapy could alleviate this problem ([@CIT0062]).

Bacteriophages {#ss11}
--------------

Bacteriophages are viruses that act as obligate parasites capable of invading bacterial cells, injecting their genomic material, and taking over the host metabolic system. These viruses can then go on to replicate inside the bacteria and produce specific proteins that can induce lysis of the bacterial cell wall (endolysin) and degradation of the polysaccharide matrix of biofilms ([@CIT0164]). Bacteriophages were first discovered about 100 years ago, but their development as therapeutic agents was dampened by the advent and success of antibiotics in the 1930s and 1940s ([@CIT0161]). Research into bacteriophages has been rejuvenated in recent years, in the search for alternative antimicrobials. [@CIT0164] undertook an in vivo study to evaluate the antimicrobial activities of bacteriophages against 2 different types of bacterial infection (MRSA and *Pseudomonas aeruginosa*) in rats. They found that when used as monotherapy, both antibiotics and bacteriophages were able to reduce the viable bacterial count. Furthermore, the combination of antibiotics and bacteriophages was able to reduce the viable bacterial count to a significantly lower level than when either agent was used as monotherapy. In addition, only the combination of antibiotic and bacteriophage resulted in significant reduction in biofilm.

Bacteriophages are inherently non-toxic, have minimal impact on the normal healthy flora, and have a lower tendency to induce resistance. Furthermore, they do not exhibit any cross-resistance with antibiotics and have good cell-penetrative ability, so they can readily disrupt and lyse biofilms ([@CIT0038], [@CIT0088], [@CIT0095]). The disadvantages of bacteriophages include their narrow spectrum of activity and their ability to induce an immune response in the mammalian host after repeated exposure, which can result in their inactivation. Moreover, the life cycle, safety considerations, the ideal route of administration (for PJI management), and the side effects of bacteriophages following clinical application are yet to be fully investigated.

Enzymes {#ss12}
-------

Certain enzymes act on the biofilm matrix, either by degrading extracellular polymeric substances (EPSs) or by sensitizing biofilms to eradication by other antimicrobial agents. 2 examples of such enzymes that are being explored are dispersin B (DspB) and deoxyribonuclease 1 (DNase 1).

*Dispersin B:* DspB is an N-acetylglucosamine enzyme produced by the Gram-negative periodontal pathogen *Actinobacillus actinomycetemcomitans*. It is capable of dispersing the biofilm exopolysaccharide poly-1,6-β-N-acetylglucosamine (PNAG), also known as PIA, which is required for full virulence of biofilm-forming bacteria ([@CIT0082], [@CIT0154], [@CIT0012]). When added to culture medium at the time of inoculation, DspB has been shown to inhibit various PNAG-producing bacteria ([@CIT0081]). In an in vitro study by [@CIT0082], DspB almost completely eradicated biofilms from the wells of a 96-well polystyrene microtiter plate after just 30 min of exposure. The authors concluded that precoating of implant surfaces with DspB may serve as an effective anti-biofilm agent.

[@CIT0035] evaluated the antimicrobial and anti-biofilm effects of vascular catheters coated with DspB and the antiseptic triclosan, against *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *E. coli*. They demonstrated, both in vitro and in vivo (using rabbits), that the combination of DspB with triclosan resulted in a significantly greater reduction in bacterial colonization than catheters coated with chlorhexidine and silver sulphasalazine and catheters that were not coated. The use of DspB as a monotherapy or in combination with other antimicrobials is being investigated with a view to being used in wound-care gels and biomaterial coatings.

*DNase 1:* DNase 1 acts by degrading extracellular bacterial DNA (eDNA), thus destabilizing biofilms, and it has been shown to suppress biofilm formation in *Staphylococcus aureus* and *Pseudomonas aeruginosa* in vitro ([@CIT0008], [@CIT0041]). Surprisingly, the disruptive capability of DNAse 1 only appears to be effective against newly formed biofilms (approximately 6 h old) in vitro, and not against mature biofilms, but it can sensitize mature biofilms to eradication by other antimicrobial agents ([@CIT0159], [@CIT0128], [@CIT0073], [@CIT0142], [@CIT0081]).

DNase 1 is currently being used clinically in the form of an aerosol (Pulmozyme) for the treatment of *Pseuomonas aeruginosa* infections in cystic fibrosis, but we are not aware of its use in PJI management.

Although the full spectrum of toxicity of these enzymes in vivo is still not known, research is under way to evaluate DspB and DNase 1 as options for use as biomaterial coating agents and skin preparatory solutions, and in fluids for wound irrigation.

Surgical management of PJI {#ss13}
--------------------------

For recent guidelines for the management of PJIs as proposed by the IDSA, see [@CIT0114].

Debridement and implant retention (DAIR) is usually considered for early infection with a stable prosthesis, and the reported success rates are between 14% and 100% ([@CIT0100], [@CIT0021], [@CIT0023], [@CIT0043], [@CIT0052], [@CIT0085], [@CIT0127], [@CIT0002], [@CIT0049], [@CIT0096]). Patients who do not qualify for DAIR and are fit enough for surgery are usually considered for either a 1-stage or 2-stage revision procedure. Recently, [@CIT0015] undertook a systematic review of unselected patients who had undergone either a 1- or 2-stage revision for an infected total hip arthroplasty. They found that there was more substantial data available for 2-stage procedures than for 1-stage procedures, probably because the 2-stage procedure has generally been more popular in previous decades. These authors concluded that there was insufficient robust evidence in the literature to ascertain which procedure was superior. [@CIT0101] undertook a similar systematic review of the available literature for 1- or 2-stage treatment of infected knee replacements. As with Beswick et al., they also concluded that there was insufficient evidence in the literature to determine which procedure was superior.

Prevention of PJI {#ss14}
=================

General strategies {#ss15}
------------------

These have already been well expounded in the literature; for reviews, see [@CIT0007], [@CIT0072], and [@CIT0004].

Novel strategies: Vaccines {#ss16}
--------------------------

Vaccines have been used successfully to control many infections, but they usually target single antigens and are developed for pathogens in their planktonic forms.

[@CIT0018] were able to generate a tetravalent vaccine using biofilm-specific antigens from *Staphylococcus aureus* osteomyelitis, which they subsequently administered to New Zealand white rabbits. They found that in combination with vancomycin therapy, the vaccine gave an 87.5% reduction in radiological and clinical signs of infection with *Staphylococcus aureus* biofilms.

Despite its success in neonate rats, clinical trials with INH-A21 (Veronate), a human immunoglobulin G with elevated levels of antibodies to the staphylococcal surface adhesin CIFA and SdrG, failed phase-III testing as it did not show any clinical benefit in neonates ([@CIT0151], [@CIT0036]).

Unfortunately, the complexities of the biofilm architecture---with multiple microbiological communities and with various sites within the communities that can express different proteins required for survival---makes the development of a single, effective anti-biofilm vaccine a considerable challenge ([@CIT0018]).

Modification of the implant surface {#ss17}
-----------------------------------

Implant coatings that resist biofilm-based infections fall into 2 caterories: (1) passive coatings, which impede bacterial adhesion and/or kill bacteria upon contact, and (2) active coatings, which release pre-incorporated antimicrobials to combat infection ([@CIT0057]).

*Passive coating:* Titanium-based implants are the most widely used in orthopedic practice, but they enhance protein layer formation, which in turn offers an ideal surface for bacteria to adhere to.

Polyethylene glycol (PEG) and polyethylene oxide (PEO) are highly hydrated polymer chains that can hamper protein absorption and bacterial adhesion to biomaterial surfaces ([@CIT0107]). Also, chemical modification of titanium surfaces with zinc can inhibit bacterial colonization ([@CIT0122]).

*Active coating:* Antibiotics can also serve as a coating for orthopedic implants. [@CIT0009] inoculated the tibias of rabbits with *Staphylococcus aureus*, followed by implantation of either gentamicin-hydroxyapatite- (HA-) coated steel K-wires, gentamicin-RGD (arginine-glycine-aspartate)-HA-coated steel K-wires, or standard HA-coated steel K-wires. After 28 days, no infection was seen in the rabbits implanted with both types of gentamicin-coated K-wires, while infection was seen in 7 of the 8 animals with the standard HA coating. Furthermore, there was good biocompatibility and bony integration of the HA implants with the supplementary coatings, similar to that of the standard HA implants ([@CIT0010]).

Similarly, [@CIT0034] reported a significantly lower rate of *Staphylococcus aureus* colonization of minocyclin-rifampicin-coated titanium-alloy pins, which were implanted into rabbit femurs and left in situ for 1 week, than with uncoated implants ([@CIT0034]).

Concerns over resistance may limit the use of antibiotics as implant coatings {#ss18}
-----------------------------------------------------------------------------

Chitosan, silver, and antimicrobial peptides (AMPs) are alternative antimicrobials to antibiotics.

*Chitosan* is a natural biocompatible cationic polysaccharide that interacts with microbial cell membranes, resulting in disruption of bacterial cells ([@CIT0013]). [@CIT0119] evaluated the efficacy of hydroxypropyltrimethyl ammonium chloride chitosan (HACC)---a quaternized derivative of chitosan with different degrees of substitution (DS; referred to as HACC 6%, 18%, and 44%)---in preventing biofilm formation on titanium surfaces in vitro. They found that HACC, especially HACC 18% and 44%, significantly inhibited biofilm formation compared to the untreated control, and was effective against both new and mature biofilms on titanium surfaces.

[@CIT0141] observed that PMMA loaded with HACC 26% was more effective in inhibiting surface biofilm formation by staphylococci than gentamicin-loaded PMMA and regular chitosan-loaded PMMA in vitro. HACC-loaded PMMA was found to downregulate the virulence-associated gene expression of antibiotic-resistant staphylococci.

[@CIT0050] showed a 46--68% decrease in bacterial contact with chitosan-heparin-modified polyethylene terephthalate (PET) films, as compared to a 7% decrease in bacterial contact with untreated PET films. Only 3--8% of viable cells remained on the modified PET films after 24 h of exposure.

*Silver* is well known for its ability to confer good anti-adhesion properties to implant surfaces without compromising osteoblastic activities, for its broad antimicrobial spectrum, for its long-lasting antibacterial effects, and for its reduced likelihood to induce resistance ([@CIT0057]). Although silver has been reported to be safe for clinical use, there is still concern about the limited availability of data on its toxicity spectrum and argyria ([@CIT0065]).

*AMPs* are natural constituents of the innate immune system of all multicellular organisms. They act either by permeabilizing microbial cell membranes or by translocating across the cell membrane to attack their cytoplasmic targets ([@CIT0011], [@CIT0058], [@CIT0061]). [@CIT0083] coated the surface of titanium with calcium phosphate (CaP) and Tet 123 (a highly potent broad-spectrum AMP) and found a 10^6^ times reduction in viable bacteria within 30 min of exposure to *Staphylococcus aureus* and *Pseudomonas aeruginosa*. The CaP-Tet 123 coating also provided a 92% surface inhibition of P. aeruginosa after 4 h and a 77% inhibition after 24 h. In related studies, [@CIT0165] and [@CIT0051] concurred that AMP coatings on biomaterials can make the implants biofilm-resistent without being toxic to osteoblast-like cells or inducing significant activation of platelets or host complement. Thus, AMP coatings can possibly be used as an antimicrobial system on orthopedic implants.

Conclusion {#ss19}
==========

Early descriptions of bacterial aggregations date back to the 1600s, when Antony van Leeuwenhoek documented the behavior of dental plaque, which he observed through a microscope ([@CIT0037], [@CIT0054]). Since then, there has been an ever-growing body of research dedicated to a better understanding of biofilms and their role in human infections, with a view to better diagnosis and eradication. Most of the studies on medically significant biofilms have been in vitro. This is understandable, as it would be impossible and unethical to subject humans to the levels of in vitro experimentation that have been and still are being performed on biofilms. Moreover, in vitro investigations have enabled scientists to undertake a wide variety of studies, which has resulted in a better understanding of the physiology of biofilms and has therefore been instrumental in the continuing development of biofilm management strategies. Caution should be exercised in extrapolating results of in vitro studies to in vivo scenarios, considering the fact that it is difficult to recreate the mechanism of the body's defense system---and the normal composition of the microenvironment found in the body---in vitro. Even so, compared to the earlier years of biofilm research, more clinical studies are being carried out nowadays following the successes of in vitro, ex vivo, and animal studies and we envisage that such clinical studies will continue in even greater numbers.

This review has hopefully enlightened readers on pertinent issues of prosthetic joint infections, and especially the role of biofilms in orthopedic implant infections.
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